RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 91 filers reported holding RHYTHM PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,029 | -99.7% | 44,874 | -44.0% | 0.01% | +200.0% |
| Q2 2022 | $332,000 | -66.2% | 80,064 | -6.0% | 0.00% | -42.9% |
| Q1 2022 | $981,000 | +7.2% | 85,182 | -7.1% | 0.01% | +40.0% |
| Q4 2021 | $915,000 | -35.9% | 91,659 | -16.1% | 0.01% | -28.6% |
| Q3 2021 | $1,427,000 | -11.0% | 109,303 | +33.5% | 0.01% | 0.0% |
| Q2 2021 | $1,603,000 | -13.2% | 81,868 | -5.7% | 0.01% | -30.0% |
| Q1 2021 | $1,846,000 | -43.9% | 86,784 | -21.6% | 0.01% | -44.4% |
| Q4 2020 | $3,291,000 | +68.2% | 110,688 | +22.6% | 0.02% | +50.0% |
| Q3 2020 | $1,957,000 | +1031.2% | 90,298 | +693.3% | 0.01% | +500.0% |
| Q1 2020 | $173,000 | -50.4% | 11,382 | -25.2% | 0.00% | -33.3% |
| Q4 2019 | $349,000 | -77.4% | 15,219 | -78.8% | 0.00% | -76.9% |
| Q3 2019 | $1,547,000 | – | 71,641 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 2,075,000 | $47,569,375 | 5.56% |
| NEA Management Company, LLC | 2,909,956 | $66,710,741 | 5.15% |
| Opaleye Management Inc. | 653,000 | $14,970,025 | 4.87% |
| Frazier Life Sciences Management, L.P. | 2,371,304 | $54,362,144 | 3.61% |
| VR Adviser, LLC | 1,090,000 | $24,988,250 | 2.63% |
| RA Capital Management | 5,676,067 | $130,123,836 | 2.56% |
| Samsara BioCapital, LLC | 345,293 | $7,915,842 | 2.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 260,537 | $5,972,811 | 1.81% |
| Logos Global Management LP | 400,000 | $9,170,000 | 1.22% |
| Cormorant Asset Management, LP | 850,000 | $19,486,250 | 1.14% |